Last reviewed · How we verify
NCT05547880
CNS Correlates of Extended Sleep Restriction
trial testing [11C]ER176 in Sleep Restriction in 13 participants. Completed in 15 March 2025.
15 March 2025
Quick facts
| Lead sponsor | Walter Reed Army Institute of Research (WRAIR) |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 13 |
| Start date | 23 May 2023 |
| Primary completion | 15 March 2025 |
| Estimated completion | 15 March 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- [11C]ER176
Conditions studied
- Sleep Restriction — all drugs for Sleep Restriction →
Sponsor
Walter Reed Army Institute of Research (WRAIR)
Who can join
Adults 18 to 39, any sex, with Sleep Restriction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Chronic sleep restriction is ubiquitous in both the general population and the military. The deleterious effects of sleep loss on human alertness and cognitive performance have been documented in numerous studies dating back to the nineteenth century. Over the past decade, evidence has emerged indicating that chronic sleep restriction may also precipitate deleterious, long lasting neuropathological changes in the brain. The purpose of this study is to determine neuropathological effects of sleep restriction and identify physiological mechanisms that correlate with sleep loss-induced performance impairment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05547880
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of [11C]ER176
Trials testing the same drug.
- NCT03912428 — Novel PET Radioligand as an Inflammatory Biomarker in Musculoskeletal Conditions · Phase 1 · terminated
Other recruiting trials for Sleep Restriction
Currently open trials in the same condition.
- NCT04037605 — Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women · EARLY_PHASE1 · active not recruiting
- NCT03377543 — Sleep and Inflammatory Resolution Pathway · EARLY_PHASE1 · active not recruiting
- NCT03142893 — Hormonal Mechanisms of Sleep Restriction - Axis Study · Phase 1 · active not recruiting
Other Walter Reed Army Institute of Research (WRAIR) trials
Trials by the same sponsor.
- NCT07533136 — Tafenoquine Combinations for Improved Radical Cure Efficacy of Plasmodium Vivax · NA · not yet recruiting
- NCT04997356 — Hostile Bias Modification Training (HBMT) Study · NA · completed
- NCT04863469 — Brain-Physical Optimization Conditioning · NA · unknown
- NCT05550610 — Evaluation of Mindfulness and Yoga in Basic Combat Training · NA · completed
- NCT04273776 — A Comparison of the Physiological and Behavioral Effects of Suvorexant and Zolpidem in Healthy Volunteers: A Randomized, · EARLY_PHASE1 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05547880 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Walter Reed Army Institute of Research (WRAIR)
- Last refreshed: 18 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05547880.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing